GSK plc (NYSE:GSK) Shares Acquired by Voloridge Investment Management LLC

Voloridge Investment Management LLC boosted its holdings in shares of GSK plc (NYSE:GSK - Free Report) by 1,360.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,165,043 shares of the pharmaceutical company's stock after purchasing an additional 2,016,795 shares during the period. Voloridge Investment Management LLC owned about 0.10% of GSK worth $73,222,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in GSK. Waverly Advisors LLC raised its stake in shares of GSK by 113.2% during the 4th quarter. Waverly Advisors LLC now owns 13,233 shares of the pharmaceutical company's stock valued at $448,000 after buying an additional 7,025 shares during the last quarter. Woodline Partners LP acquired a new stake in GSK during the fourth quarter worth about $36,665,000. Vestal Point Capital LP grew its holdings in GSK by 233.3% during the fourth quarter. Vestal Point Capital LP now owns 1,000,000 shares of the pharmaceutical company's stock worth $33,820,000 after acquiring an additional 700,000 shares during the period. Vident Advisory LLC raised its position in GSK by 4.2% during the fourth quarter. Vident Advisory LLC now owns 20,080 shares of the pharmaceutical company's stock valued at $679,000 after acquiring an additional 813 shares in the last quarter. Finally, Visionary Wealth Advisors lifted its holdings in GSK by 5.6% in the fourth quarter. Visionary Wealth Advisors now owns 193,378 shares of the pharmaceutical company's stock valued at $6,540,000 after acquiring an additional 10,178 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Price Performance

GSK traded down $0.23 during midday trading on Monday, hitting $38.70. 3,666,936 shares of the company traded hands, compared to its average volume of 4,836,207. The business has a 50 day simple moving average of $37.27 and a two-hundred day simple moving average of $36.02. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.01. The company has a market capitalization of $79.84 billion, a price-to-earnings ratio of 24.34, a PEG ratio of 1.12 and a beta of 0.51. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. GSK had a net margin of 8.13% and a return on equity of 48.59%. The firm had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. During the same period last year, the company posted $0.43 EPS. GSK's quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be paid a $0.4216 dividend. The ex-dividend date is Friday, May 16th. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.36%. GSK's payout ratio is currently 86.60%.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Wall Street Zen raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 24th. Morgan Stanley began coverage on shares of GSK in a report on Wednesday, February 12th. They set an "equal weight" rating on the stock. BNP Paribas began coverage on shares of GSK in a report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price objective for the company. Finally, Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, GSK has a consensus rating of "Moderate Buy" and an average target price of $40.58.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.